Trial Profile
A study to examine neutrophil-lymphocyte ratio as a predictor of outcomes in patients with hepatocellular carcinoma treated with transcatheter arterial embolization combined with Sorafenib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 11 Dec 2015 New trial record